Medical Therapeutic Company Receives Ethics Committee Approval For Cancer Trial

Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on advancing treatments for cancer and life-threatening infectious diseases, has recently received recognition for its innovative Hemopurifier® technology. On August 6, 2024, the Bellberry Human Research Ethics Committee (BHREC) granted full ethics approval to the Pindara Private Hospital for a clinical trial aimed at assessing the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatments, such as Merck's Keytruda® (pembrolizumab) or Bristol Myers Squibb's Opdivo® (nivolumab). $Aethlon Medical (AEMD.US)$